Clinical Report: Top 10 States Offering Large Physician Loan Repayment Programs
Background
Physician loan repayment programs vary by state based on award amounts, specialty eligibility, service commitments, and practice location requirements. These programs provide financial incentives for physicians to practice in underserved areas.
Data Highlights
State
Program
Award Amount
Service Commitment
Michigan
Michigan State Loan Repayment Program
Up to $300,000
Up to 10 years
Iowa
Rural Iowa Primary Care Loan Repayment Program
Up to $200,000
Varies
Nebraska
Nebraska State Loan Repayment Program
$60,000/year
3 years
New Jersey
Primary Care Practitioner Loan Redemption Program
Up to $120,000
2 to 4 years
Louisiana
Louisiana Physician Loan Repayment Program
$30,000/year
5 years
Maryland
Maryland Loan Repayment Programs
Up to $100,000
2 years
New York
Doctors Across New York Physician Loan Repayment Program
Up to $120,000
3 years
Delaware
Delaware State Loan Repayment Program
Up to $100,000
2 years
Minnesota
Health Care Loan Forgiveness Programs
Up to $33,000/year
3 to 4 years
Colorado
Colorado Health Service Corps
Up to $90,000
3 years
Key Findings
Michigan offers up to $300,000 for physicians in underserved areas.
Iowa provides up to $200,000 for specific specialties in eligible areas.
Nebraska's programs can total up to $200,000 for physicians and dentists.
New Jersey's program allows for up to $120,000 in loan redemption for primary care providers.
Maryland offers up to $100,000 for a 2-year service commitment.
Colorado's program provides up to $90,000 for a 3-year commitment in shortage areas.
Clinical Implications
Physicians considering practice in underserved areas may find significant financial support through state loan repayment programs. Understanding the eligibility and commitment requirements of these programs can aid in career planning and addressing workforce shortages in healthcare.
Conclusion
State-sponsored loan repayment programs play a vital role in incentivizing physicians to serve in underserved communities, thereby improving access to healthcare services.
Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.
Analysis of East Asian genetic data found a modest inverse association between rheumatoid arthritis susceptibility and periodontitis risk, though researchers said the findings require confirmation in independent cohorts.
